Glass House Brands (GLAS) Other Non-Current Assets (2020 - 2026)
Glass House Brands' (GLAS) quarterly Other Non-Current Assets came in at $435000.0 in Q1 2026, down 83.05% year-on-year from $2.6 million in Q1 2025, and down 58.96% on a QoQ basis from $1.1 million in Q4 2025.
Glass House Brands (GLAS) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Other Non-Current Assets data on file, last reported at $435000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 83.05% year-over-year to $435000.0 in Q1 2026; TTM through Mar 2026 was $435000.0, a 83.05% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 64.67% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $435000.0, down from $1.1 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for GLAS reached as high as $4.9 million in Q3 2024 and fell as low as $435000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $3.3 million across 5 years, with a median of $3.6 million in 2023.
- Across the five-year window, Other Non-Current Assets surged 2187.6% in 2022 and slumped 83.05% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $4.7 million in 2022, then declined by 4.67% to $4.5 million in 2023, then tumbled by 32.93% to $3.0 million in 2024, then slumped by 64.67% to $1.1 million in 2025, then sank by 58.96% to $435000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $435000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 169,000.00 |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 435,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.48 Mn |
| Dec 31, 2023 | 4.47 Mn |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Dec 31, 2022 | 4.69 Mn |
| Sep 30, 2022 | 3.67 Mn |
| Jun 30, 2022 | 3.63 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Dec 31, 2021 | 2.34 Mn |
| Sep 30, 2021 | 160,478.00 |
| Mar 31, 2021 | 431,409.00 |